>> Someone, Rick, Biowa, PB, Peter, David K., Gordon, RW Reeves, Bob L, bring me back to earth. <<
Isn't going be me, just watching and learning. As described in the release, looks awfully good.
Naive questions, not questions with an agenda.... I don't own "either stock", and I want both companies to be successful......
Fourteen of the 38 patients were evaluable for response.... is this low? Have they indicated what happened to the other 24 patients? Does this mean that, on an intent to treat basis, the response was low? That may not be a fair question, as patients were 16-18 weeks into the protocol before they saw iodine (correct?).
At the thirteenth week, following treatment with tositumomab, iodine I 131 tositumomab, the rate of complete
response increased to 43 percent (six out of 14 patients). At approximately six months, 71 percent of patients (10 out of 14)
had experienced a complete response.
Any oncologists out there? Hmmmm....... four patients continued to "respond" at beyond 13 weeks. A new species of iodine.
Due to the immunosuppressive effect of fludarabine, only one patient developed human anti-mouse antibodies
I won't question that only one patient made HAMA, but I'd like to know what the definition of a response was in relationship to the stringency of assay. Also, does it strike anyone else as curious that humans can't make good antibody responses at 6-8 weeks post fludarabine? |
